Tag: Biotech and Pharma

AbbVie and Iambic Therapeutics announced a multi-year collaboration to apply Iambic’s artificial intelligence platform to small molecule drug discovery 

Novo Nordisk said on Monday its ​next-generation experimental drug, CagriSema, delivered an ‌estimated average weight loss of 12.4% in a late-stage trial in patients with diabetes, outperforming ​Eli Lilly’s rival drug.

Novo set out its 2030 strategic ambitions at a Capital Markets Day in London on Monday, but the plan failed to satisfy investors hoping for a more decisive turnaround.

Xenon Pharmaceuticals said it submitted a regulatory filing for its lead drug candidate that puts it on the brink of its first commercial product.

Σημαντική αύξηση των ενοποιημένων πωλήσεων προ claw back και rebate κατά 24,1% το α’ εξάμηνο κατέγραψε ο όμιλος Lavipharm ενώ τα κέρδη EBITDA από συνεχιζόμενες δραστηριότητες αυξήθηκαν κατά 5,2%.

Novo Nordisk on Monday said it is rebranding its name to “Novo” and updating its corporate culture, as the company works to win back market share in the obesity drug space. 

 A major shareholder in Novartis has called for a shake-up of the Swiss drugmaker’s board to improve corporate governance after its shares suffered a record fall this week ​following back-to-back trial setbacks.

Novartis AG shares fell over 3% on Monday, after the drugmaker on Friday said its experimental drug pelacarsen failed to reduce the risk of heart attacks, strokes and other serious heart problems in a major late-stage trial, dealing a setback to its cardiovascular drug pipeline.

Swiss drugmaker Novartis said on Tuesday its oral drug remibrutinib outperformed an ‌older treatment in reducing relapses in patients with a form of multiple sclerosis, boosting hopes the medicine could become a blockbuster product.

Eli Lilly  continued its acquisition spree on Monday as the world’s largest drugmaker agreed to pay roughly $2.9 billion in cash for a biotechnology company developing treatments for autoimmune diseases.

Moderna plans to raise $2 billion by selling convertible senior notes due 2032, with proceeds earmarked for its cancer vaccine business and debt repayment, the company said Thursday.

Abbott agreed to pay $670 million to resolve a lawsuit over its specialty formulas for premature infants as well as about 2,000 related claims.

An experimental personalized cancer vaccine from Merck and Moderna showed positive initial results in its first-ever late-stage trial, the companies announced Wednesday, bringing them one step closer to filing for approval of the treatment option.

Coloplast shares climbed 3.5% on Tuesday, after the Danish medical device maker beat sales expectations in its fiscal third quarter, offsetting a miss on profit margins tied to reimbursement setbacks in its Biologics unit and currency headwinds.

AstraZeneca said Monday it is discontinuing a late-stage trial testing its drug volrustomig, combined with chemotherapy, in patients with metastatic non-small cell lung cancer.

Hims & Hers Health reported a net loss of $86.3 million in the second quarter of 2026, swinging from net income of $42.5 million in the same period a year earlier, even as revenue climbed 38% to $753.2 million.

Cardinal Health  reported fourth quarter EPS of $2.60, $0.19 better than the analyst estimate of $2.41. Revenue for the quarter came in at $63.7B versus the consensus estimate of $65.22B.

Shares of Doximity surged more than 80% in premarket trading Friday after the medical networking and telehealth platform missed analysts’ earnings target.

“Flu remains a significant public health challenge, and mFLUSIVA provides an important new option for America’s seniors. This approval also reflects the ongoing potential of our mRNA platform,” Moderna CEO Stéphane Bancel said.

There are “no discussions” ongoing between AstraZeneca and ​Bristol Myers Squibb over a potential ‌deal, a senior source close to the matter told Reuters on Wednesday, quashing the ​prospect of a mooted mega merger ​between the drugmakers.